Liposomal doxorubicin: the good, the bad and the not-so-ugly

J. Szebeni, Tamás Fülöp, László Dézsi, Bart Metselaar, Gert Storm

Research output: Article

7 Citations (Scopus)

Abstract

There are direct and indirect indications that PEGylated liposomal doxorubicin (Doxil), a widely used anticancer nanomedicine, has a subclinical immune suppressive effect. As an example of a seemingly bad pharmacological property turning out to be “not-so-ugly”, but actually beneficial, the authors highlight the potential benefits of Doxil's immune suppressive effect. These include (1) the decreased uptake of the drug by the MPS which may entail enhanced tumor uptake, and, hence, improved therapeutic efficacy; (2) the use of slow infusion protocols in reducing the risk of hypersensitivity (infusion) reactions; and (3), possible protection against hypersensitivity reactions to co-administered reactogenic drugs. To consider immune suppression as useful represents a paradigm shifts in nanotoxicology and anticancer chemotherapy.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalJournal of Drug Targeting
DOIs
Publication statusAccepted/In press - ápr. 26 2016

Fingerprint

Hypersensitivity
Nanomedicine
Pharmaceutical Preparations
Pharmacology
Drug Therapy
liposomal doxorubicin
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Liposomal doxorubicin : the good, the bad and the not-so-ugly. / Szebeni, J.; Fülöp, Tamás; Dézsi, László; Metselaar, Bart; Storm, Gert.

In: Journal of Drug Targeting, 26.04.2016, p. 1-3.

Research output: Article

Szebeni, J. ; Fülöp, Tamás ; Dézsi, László ; Metselaar, Bart ; Storm, Gert. / Liposomal doxorubicin : the good, the bad and the not-so-ugly. In: Journal of Drug Targeting. 2016 ; pp. 1-3.
@article{e8a1b51b13b14d9dbeebdb45a220bad0,
title = "Liposomal doxorubicin: the good, the bad and the not-so-ugly",
abstract = "There are direct and indirect indications that PEGylated liposomal doxorubicin (Doxil), a widely used anticancer nanomedicine, has a subclinical immune suppressive effect. As an example of a seemingly bad pharmacological property turning out to be “not-so-ugly”, but actually beneficial, the authors highlight the potential benefits of Doxil's immune suppressive effect. These include (1) the decreased uptake of the drug by the MPS which may entail enhanced tumor uptake, and, hence, improved therapeutic efficacy; (2) the use of slow infusion protocols in reducing the risk of hypersensitivity (infusion) reactions; and (3), possible protection against hypersensitivity reactions to co-administered reactogenic drugs. To consider immune suppression as useful represents a paradigm shifts in nanotoxicology and anticancer chemotherapy.",
keywords = "Allergic reactions, anaphylaxis, complement, drug delivery, hypersensitivity, liposomes, phospholipids",
author = "J. Szebeni and Tam{\'a}s F{\"u}l{\"o}p and L{\'a}szl{\'o} D{\'e}zsi and Bart Metselaar and Gert Storm",
year = "2016",
month = "4",
day = "26",
doi = "10.3109/1061186X.2016.1172591",
language = "English",
pages = "1--3",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Liposomal doxorubicin

T2 - the good, the bad and the not-so-ugly

AU - Szebeni, J.

AU - Fülöp, Tamás

AU - Dézsi, László

AU - Metselaar, Bart

AU - Storm, Gert

PY - 2016/4/26

Y1 - 2016/4/26

N2 - There are direct and indirect indications that PEGylated liposomal doxorubicin (Doxil), a widely used anticancer nanomedicine, has a subclinical immune suppressive effect. As an example of a seemingly bad pharmacological property turning out to be “not-so-ugly”, but actually beneficial, the authors highlight the potential benefits of Doxil's immune suppressive effect. These include (1) the decreased uptake of the drug by the MPS which may entail enhanced tumor uptake, and, hence, improved therapeutic efficacy; (2) the use of slow infusion protocols in reducing the risk of hypersensitivity (infusion) reactions; and (3), possible protection against hypersensitivity reactions to co-administered reactogenic drugs. To consider immune suppression as useful represents a paradigm shifts in nanotoxicology and anticancer chemotherapy.

AB - There are direct and indirect indications that PEGylated liposomal doxorubicin (Doxil), a widely used anticancer nanomedicine, has a subclinical immune suppressive effect. As an example of a seemingly bad pharmacological property turning out to be “not-so-ugly”, but actually beneficial, the authors highlight the potential benefits of Doxil's immune suppressive effect. These include (1) the decreased uptake of the drug by the MPS which may entail enhanced tumor uptake, and, hence, improved therapeutic efficacy; (2) the use of slow infusion protocols in reducing the risk of hypersensitivity (infusion) reactions; and (3), possible protection against hypersensitivity reactions to co-administered reactogenic drugs. To consider immune suppression as useful represents a paradigm shifts in nanotoxicology and anticancer chemotherapy.

KW - Allergic reactions

KW - anaphylaxis

KW - complement

KW - drug delivery

KW - hypersensitivity

KW - liposomes

KW - phospholipids

UR - http://www.scopus.com/inward/record.url?scp=84973863174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973863174&partnerID=8YFLogxK

U2 - 10.3109/1061186X.2016.1172591

DO - 10.3109/1061186X.2016.1172591

M3 - Article

C2 - 27030293

AN - SCOPUS:84973863174

SP - 1

EP - 3

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

ER -